Stock CDTX CIDARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Delayed Nasdaq
Other stock markets
 03:00:35 2024-06-07 pm EDT 		5-day change 1st Jan Change
12.98 USD -2.95% Intraday chart for Cidara Therapeutics, Inc. +2.13% -18.39%
May. 15 Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M MT
May. 15 Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
AQ
Cidara Therapeutics: Q1 Earnings Snapshot
AQ
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M
MT
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
AQ
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
PR
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
AQ
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
BU
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE
AQ
Top Premarket Gainers
MT
North American Morning Briefing : More Tech -2-
DJ
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty
DJ
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
DJ
Transcript : Cidara Therapeutics, Inc. - Special Call
Cidara Therapeutics, Inc. Announces Board Changes
CI
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
AQ
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..
CI
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDTX Stock
  4. News Cidara Therapeutics, Inc.